Données d’efficacité et de tolérance en vie réelle du cétuximab dans le carcinome épidermoïde cutané avancé : étude nationale rétrospective et multicentrique

Montaudié, Henri; Kogay, Maria; Viotti, Julien; Combemale, P.; Dutriaux, Caroline; Dupin, Nicolas; Robert, Caroline; Mortier, Laurent; Duval-Modeste, A.-B.; Dalle, S.; Quatrebarbes, Julie De; Stefan, A.; Brunet‐Possenti, F.; Picard, A.; Poissonnet, G.; Peyrade, Fréd́eric

doi:10.1016/j.annder.2018.09.257

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Anti‐EGFR antibodies in monotherapy have yielded interesting results in these patients. Among them, cetuximab is used most frequently 5–14 . In a phase 2 trial including 36 patients, the best overall response rate was 28%, median progression‐free survival was 4.1 months and average overall survival was 8.1 months 5 .…”

Section: Introductionmentioning

confidence: 99%

“…Among them, cetuximab is used most frequently. [5][6][7][8][9][10][11][12][13][14] In a phase 2 trial including 36 patients, the best overall response rate was 28%, median progression-free survival was 4.1 months and average overall survival was 8.1 months. 5 Only one prospective phase 2 study has been conducted on panitumumab, yielding a best overall response rate of 31%, a median progression-free survival of 8 months and a median overall survival of 11 months.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and safety of panitumumab alone or in association with radiotherapy in unresectable cutaneous squamous cell carcinoma

Hourbeigt

Ehret

Durlach³

et al. 2020

Acad Dermatol Venereol

View full text Add to dashboard Cite

Background The prognosis of unresectable cutaneous squamous cell carcinomas is very poor. Objective To evaluate the efficacy and safety of panitumumab alone or in association with radiotherapy in the treatment of unresectable cutaneous squamous cell carcinoma. Methods This was a monocentre retrospective study of all consecutive patients having received at least two courses of panitumumab, alone or in association with radiotherapy, between 2016 and 2019. The primary endpoint was the rate of best overall response, evaluated according to the RECIST 1.1 criteria. The secondary endpoints were the response and disease control rates at 6 weeks and 6 months, progression-free survival, overall survival and safety. Results A total of 25 patients were included; their median age was 86 years, and 17 (86%) had a WHO performance status over 2. The best overall response rate was 52%, including four complete responses (16%) and nine partial responses (36%). All patients with complete response and five out of nine patients with partial response had received concurrent radiotherapy, in most cases in moderate to low doses (<40 Gray, 67%). The response rates at 6 weeks and 6 months were 12% and 28%, respectively. The control rates at 6 weeks and 6 months were 84% and 32%, respectively. Median progression-free survival was 6.9 months, and median overall survival was 10.5 months. Grade 3 side-effects, mostly dermatological, occurred in 16 patients (64%). Conclusion These results suggest that panitumumab remains pertinent in the treatment of unresectable cutaneous squamous cell carcinoma, in particular in association with radiotherapy, despite recent advances with anti-PD-1 antibodies. It presents several advantages: it can be used in very elderly or feeble patients, it does not provoke anaphylactic or other irreversible or life-threatening side-effects, and our study observed some long-term responses. Further prospective investigation of anti-EGFR antibodies, in association with anti-PD-1 antibodies and/or chemotherapy, should be conducted.

show abstract

Section: Introductionmentioning

confidence: 99%